These high-flying stocks could have more room to run if analysts are right.
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre